147 related articles for article (PubMed ID: 32336824)
21. The Association of Background Parenchymal Enhancement at Breast MRI with Breast Cancer: A Systematic Review and Meta-Analysis.
Thompson CM; Mallawaarachchi I; Dwivedi DK; Ayyappan AP; Shokar NK; Lakshmanaswamy R; Dwivedi AK
Radiology; 2019 Sep; 292(3):552-561. PubMed ID: 31237494
[TBL] [Abstract][Full Text] [Related]
22. MRI background parenchymal enhancement, fibroglandular tissue, and mammographic breast density in patients with invasive lobular breast cancer on adjuvant endocrine hormonal treatment: associations with survival.
Lo Gullo R; Daimiel I; Rossi Saccarelli C; Bitencourt A; Sevilimedu V; Martinez DF; Jochelson MS; Morris EA; Reiner JS; Pinker K
Breast Cancer Res; 2020 Aug; 22(1):93. PubMed ID: 32819432
[TBL] [Abstract][Full Text] [Related]
23. Role of dynamic contrast-enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER-positive, HER2-negative, node-negative invasive breast cancer.
Shin GW; Zhang Y; Kim MJ; Su MY; Kim EK; Moon HJ; Yoon JH; Park VY
J Magn Reson Imaging; 2018 Dec; 48(6):1678-1689. PubMed ID: 29734483
[TBL] [Abstract][Full Text] [Related]
24. Response Predictivity to Neoadjuvant Therapies in Breast Cancer: A Qualitative Analysis of Background Parenchymal Enhancement in DCE-MRI.
La Forgia D; Vestito A; Lasciarrea M; Comes MC; Diotaiuti S; Giotta F; Latorre A; Lorusso V; Massafra R; Palmiotti G; Rinaldi L; Signorile R; Gatta G; Fanizzi A
J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33915842
[TBL] [Abstract][Full Text] [Related]
25. Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study.
Watt GP; Sung J; Morris EA; Buys SS; Bradbury AR; Brooks JD; Conant EF; Weinstein SP; Kontos D; Woods M; Colonna SV; Liang X; Stein MA; Pike MC; Bernstein JL
Breast Cancer Res; 2020 Dec; 22(1):138. PubMed ID: 33287857
[TBL] [Abstract][Full Text] [Related]
26. Background parenchymal enhancement on breast MRI and mammographic breast density: correlation with tumour characteristics.
Kim MY; Choi N; Yang JH; Yoo YB; Park KS
Clin Radiol; 2015 Jul; 70(7):706-10. PubMed ID: 25824280
[TBL] [Abstract][Full Text] [Related]
27. Does breast MRI background parenchymal enhancement indicate metabolic activity? Qualitative and 3D quantitative computer imaging analysis.
Mema E; Mango VL; Guo X; Karcich J; Yeh R; Wynn RT; Zhao B; Ha RS
J Magn Reson Imaging; 2018 Mar; 47(3):753-759. PubMed ID: 28646614
[TBL] [Abstract][Full Text] [Related]
28. Background Parenchymal Enhancement and Fibroglandular Tissue Proportion on Breast MRI: Correlation with Hormone Receptor Expression and Molecular Subtypes of Breast Cancer.
Öztürk M; Polat AV; Süllü Y; Tomak L; Polat AK
J Breast Health; 2017 Jan; 13(1):27-33. PubMed ID: 28331765
[TBL] [Abstract][Full Text] [Related]
29. The correlation of background parenchymal enhancement in the contralateral breast with patient and tumor characteristics of MRI-screen detected breast cancers.
Vreemann S; Gubern-Mérida A; Borelli C; Bult P; Karssemeijer N; Mann RM
PLoS One; 2018; 13(1):e0191399. PubMed ID: 29351560
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment MRI features associated with diagnostic accuracy of post-treatment MRI after neoadjuvant chemotherapy.
Eun NL; Gweon HM; Son EJ; Youk JH; Kim JA
Clin Radiol; 2018 Jul; 73(7):676.e9-676.e14. PubMed ID: 29567270
[TBL] [Abstract][Full Text] [Related]
31. Could parenchymal enhancement on contrast-enhanced spectral mammography (CESM) represent a new breast cancer risk factor? Correlation with known radiology risk factors.
Savaridas SL; Taylor DB; Gunawardana D; Phillips M
Clin Radiol; 2017 Dec; 72(12):1085.e1-1085.e9. PubMed ID: 28870431
[TBL] [Abstract][Full Text] [Related]
32. MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
Goorts B; Dreuning KMA; Houwers JB; Kooreman LFS; Boerma EG; Mann RM; Lobbes MBI; Smidt ML
Breast Cancer Res; 2018 Apr; 20(1):34. PubMed ID: 29669584
[TBL] [Abstract][Full Text] [Related]
33. Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging.
King V; Kaplan J; Pike MC; Liberman L; David Dershaw D; Lee CH; Brooks JD; Morris EA
Breast J; 2012; 18(6):527-34. PubMed ID: 23002953
[TBL] [Abstract][Full Text] [Related]
34. MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women.
Brooks JD; Christensen RAG; Sung JS; Pike MC; Orlow I; Bernstein JL; Morris EA
NPJ Breast Cancer; 2022 Aug; 8(1):97. PubMed ID: 36008488
[TBL] [Abstract][Full Text] [Related]
35. High-background parenchymal enhancement in the contralateral breast is an imaging biomarker for favorable prognosis in patients with triple-negative breast cancer treated with chemotherapy.
Xu C; Yu J; Wu F; Li X; Hu D; Chen G; Wu G
Am J Transl Res; 2021; 13(5):4422-4436. PubMed ID: 34150024
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of background parenchymal enhancement in breast contrast-enhanced ultrasound with Sonazoid
Haga M; Hirai T; Nakai T; Kobayashi T; Nakamura T; Marugami A; Ito T; Takewa M; Marugami N; Kichikawa K
J Med Ultrason (2001); 2020 Oct; 47(4):591-601. PubMed ID: 32989596
[TBL] [Abstract][Full Text] [Related]
37. Background parenchymal enhancement and fibroglandular tissue on breast MRI in women with high genetic risk: Are changes before and after risk-reducing salpingo-oophorectomy associated with breast cancer risk?
Bermot C; Saint-Martin C; Malhaire C; Sebbag-Sfez D; Mouret-Fourme E; Carton M; Thibault FE
Eur J Radiol; 2018 Dec; 109():171-177. PubMed ID: 30527300
[TBL] [Abstract][Full Text] [Related]
38. Effect of Background Parenchymal Enhancement on Cancer Risk Across Different High-Risk Patient Populations Undergoing Screening Breast MRI.
Sippo DA; Rutledge GM; Burk KS; Mercaldo SF; Dontchos BN; Edmonds CE; Lehman CD
AJR Am J Roentgenol; 2019 Mar; 212(6):1412-1418. PubMed ID: 30888867
[TBL] [Abstract][Full Text] [Related]
39. Quantitative Assessment of Breast Parenchymal Uptake on 18F-FDG PET/CT: Correlation with Age, Background Parenchymal Enhancement, and Amount of Fibroglandular Tissue on MRI.
Leithner D; Baltzer PA; Magometschnigg HF; Wengert GJ; Karanikas G; Helbich TH; Weber M; Wadsak W; Pinker K
J Nucl Med; 2016 Oct; 57(10):1518-1522. PubMed ID: 27230924
[TBL] [Abstract][Full Text] [Related]
40. Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer: comparison of diagnostic performances of dedicated breast PET, whole-body PET, and dynamic contrast-enhanced MRI.
Tokuda Y; Yanagawa M; Fujita Y; Honma K; Tanei T; Shimoda M; Miyake T; Naoi Y; Kim SJ; Shimazu K; Hamada S; Tomiyama N
Breast Cancer Res Treat; 2021 Jul; 188(1):107-115. PubMed ID: 33730265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
